Oleanolic acid (OA), which is a natural pentacyclic terpenoid, has been identified for hepato-protective, nephron-protective and cardio-tonic properties. In contrast, doxorubicin (DOX) is a famous anti-cancer drug but its efficacy is a question mark because of its known cardio-toxicity. We developed a combined nanoliposomal formulation of DOX with OA, as adjuvant, to overwhelm toxic effects of DOX without compromising anticancer activity. The entrapment efficiency and the particle size were brought in limit by the reengineered ethanolic injection method (REIM), without further extrusion. The developed formulations were stable over the study period of two months. A modified HPLC method was employed for the analysis of OA (drug retention time, Tr = 12 ± 1 min). The recovery of OA against spiked plasma samples was more than 90%. MTT assay showed anti-apoptotic synergism against HepG2 cells at non-fixed ratio (combination index, CI < 1). A sustained in vivo drug release of experimental drugs was depicted over 24 h. Histopathological examination and laboratory findings indicated no visible sign of toxicity in the treated mice group against combined delivery. Hence, this combined nanoliposomal formulation was tagged as a safer therapy for the DOX based cancer treatments.

Respiratory diseases are leading causes of death and disability around the globe, with a diverse range of health problems. Treatment of respiratory diseases and infections has been verified to be thought-provoking because of the increasing incidence and mortality rate. Hydrogen sulfide (H₂S) is one of the recognized gaseous transmitters involved in an extensive range of cellular functions, and physiological and pathological processes in a variety of diseases, including respiratory diseases. Recently, the therapeutic potential of H₂S for respiratory diseases has been widely investigated. H₂S plays a vital therapeutic role in obstructive respiratory disease, pulmonary fibrosis, emphysema, pancreatic inflammatory/respiratory lung injury, pulmonary inflammation, bronchial asthma and bronchiectasis. Although the therapeutic role of H₂S has been extensively studied in various respiratory diseases, a concrete literature review will have an extraordinary impact on future therapeutics. This review provides a comprehensive overview of the effective role of H₂S in respiratory diseases. Besides, we also summarized H₂S production in the lung and its metabolism processes in respiratory diseases.

Quince seed mucilage, as a polymer, has been studied for tailoring drug delivery systems for pH‐specific drug release. The antidiabetic properties of this polymer are well studied, but its effect in drug carrier systems is unknown in diabetes therapy. Quince seed mucilage comprising hybrid calcium carbonate composites loaded with metformin was developed via coprecipitation technique to assess their effectiveness in diabetes treatment. They were evaluated for entrapment efficiency, in vitro release profile, surface morphology, and other physicochemical characterizations. The in vivo assessment was conducted for 28 days in diabetic rats to monitor blood glucose levels and body weight. The developed composites exhibited a sustained in vitro release profile, where the drug release was slow and pH‐dependent with optimum entrapment efficiency (82%). The surface morphology study revealed a homogeneous rhombohedral structure of developed composites. Moreover, the animal study signifies the blood glucose–lowering effect of developed composites which was 9.49% for blank composites and 65.7% for metformin‐loaded composites after 28 days in diabetic rats. Furthermore, metformin‐loaded composites were able to significantly revive the body weight reduction in diabetic rats as compared to the drug solution. These composites improved body weight and blood glucose levels in in vivo studies as compared to the control group, indicating their potential application in drug delivery. This study provides new insights into diabetes research and introduces a carrier system that assists in diabetes management in conjunction with the drug.